KR101565964B1 - Composition Comprising Water Extracts from Pleurotus eryngii var. ferulea (Pf.). for Treating or Preventing hyperlipidemia - Google Patents
Composition Comprising Water Extracts from Pleurotus eryngii var. ferulea (Pf.). for Treating or Preventing hyperlipidemia Download PDFInfo
- Publication number
- KR101565964B1 KR101565964B1 KR1020120143701A KR20120143701A KR101565964B1 KR 101565964 B1 KR101565964 B1 KR 101565964B1 KR 1020120143701 A KR1020120143701 A KR 1020120143701A KR 20120143701 A KR20120143701 A KR 20120143701A KR 101565964 B1 KR101565964 B1 KR 101565964B1
- Authority
- KR
- South Korea
- Prior art keywords
- mushroom
- composition
- water extract
- present
- water
- Prior art date
Links
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 title claims abstract description 64
- 239000000284 extract Substances 0.000 title claims abstract description 61
- 239000000203 mixture Substances 0.000 title claims abstract description 31
- 208000031226 Hyperlipidaemia Diseases 0.000 title claims abstract description 19
- 244000252132 Pleurotus eryngii Species 0.000 title claims description 5
- 235000001681 Pleurotus eryngii Nutrition 0.000 title claims description 5
- 235000001674 Agaricus brunnescens Nutrition 0.000 claims abstract description 51
- 239000004480 active ingredient Substances 0.000 claims abstract description 15
- 235000013376 functional food Nutrition 0.000 claims abstract description 11
- 239000000843 powder Substances 0.000 claims description 16
- 235000013361 beverage Nutrition 0.000 claims description 11
- 235000013305 food Nutrition 0.000 claims description 11
- 239000003826 tablet Substances 0.000 claims description 6
- 239000008187 granular material Substances 0.000 claims description 4
- 239000006228 supernatant Substances 0.000 claims description 4
- 239000000839 emulsion Substances 0.000 claims description 3
- 239000000706 filtrate Substances 0.000 claims description 3
- 238000002347 injection Methods 0.000 claims description 3
- 239000007924 injection Substances 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 150000003839 salts Chemical class 0.000 claims description 3
- 239000000725 suspension Substances 0.000 claims description 3
- 239000006188 syrup Substances 0.000 claims description 3
- 235000020357 syrup Nutrition 0.000 claims description 3
- 235000013373 food additive Nutrition 0.000 claims description 2
- 239000002778 food additive Substances 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 32
- 235000006533 astragalus Nutrition 0.000 abstract description 17
- 241001061264 Astragalus Species 0.000 abstract description 15
- 210000004233 talus Anatomy 0.000 abstract description 15
- 150000001840 cholesterol esters Chemical class 0.000 abstract description 7
- 238000010521 absorption reaction Methods 0.000 abstract description 6
- 230000007935 neutral effect Effects 0.000 abstract 1
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 24
- 230000002401 inhibitory effect Effects 0.000 description 15
- 238000004519 manufacturing process Methods 0.000 description 13
- 239000000796 flavoring agent Substances 0.000 description 12
- 235000019634 flavors Nutrition 0.000 description 12
- 235000012000 cholesterol Nutrition 0.000 description 11
- 239000004615 ingredient Substances 0.000 description 11
- 239000003814 drug Substances 0.000 description 9
- 238000000605 extraction Methods 0.000 description 8
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- 102000004190 Enzymes Human genes 0.000 description 7
- 108090000790 Enzymes Proteins 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 7
- 230000001906 cholesterol absorption Effects 0.000 description 7
- 229940088598 enzyme Drugs 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 150000001720 carbohydrates Chemical class 0.000 description 6
- 235000014633 carbohydrates Nutrition 0.000 description 6
- 239000000546 pharmaceutical excipient Substances 0.000 description 6
- 102000019280 Pancreatic lipases Human genes 0.000 description 5
- 108050006759 Pancreatic lipases Proteins 0.000 description 5
- 230000009102 absorption Effects 0.000 description 5
- 230000000052 comparative effect Effects 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 229940116369 pancreatic lipase Drugs 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
- 229930006000 Sucrose Natural products 0.000 description 4
- 125000002252 acyl group Chemical group 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 238000007796 conventional method Methods 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 201000005577 familial hyperlipidemia Diseases 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 235000019359 magnesium stearate Nutrition 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 239000008213 purified water Substances 0.000 description 4
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 4
- 239000005720 sucrose Substances 0.000 description 4
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 4
- 229940088594 vitamin Drugs 0.000 description 4
- 229930003231 vitamin Natural products 0.000 description 4
- 235000013343 vitamin Nutrition 0.000 description 4
- 239000011782 vitamin Substances 0.000 description 4
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 3
- 239000004386 Erythritol Substances 0.000 description 3
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 229930195725 Mannitol Natural products 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 235000019414 erythritol Nutrition 0.000 description 3
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 3
- 229940009714 erythritol Drugs 0.000 description 3
- 235000020510 functional beverage Nutrition 0.000 description 3
- 235000013402 health food Nutrition 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 229910052500 inorganic mineral Inorganic materials 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 239000000594 mannitol Substances 0.000 description 3
- 235000010355 mannitol Nutrition 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 229940126601 medicinal product Drugs 0.000 description 3
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 3
- 239000011707 mineral Substances 0.000 description 3
- 235000010755 mineral Nutrition 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 235000010356 sorbitol Nutrition 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- 235000012222 talc Nutrition 0.000 description 3
- 150000003722 vitamin derivatives Chemical class 0.000 description 3
- 239000000811 xylitol Substances 0.000 description 3
- 235000010447 xylitol Nutrition 0.000 description 3
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 3
- 229960002675 xylitol Drugs 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 235000003261 Artemisia vulgaris Nutrition 0.000 description 2
- 240000006891 Artemisia vulgaris Species 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 108010011485 Aspartame Proteins 0.000 description 2
- 241000045403 Astragalus propinquus Species 0.000 description 2
- 102100035687 Bile salt-activated lipase Human genes 0.000 description 2
- 229940122502 Cholesterol absorption inhibitor Drugs 0.000 description 2
- 206010011224 Cough Diseases 0.000 description 2
- 229920000858 Cyclodextrin Polymers 0.000 description 2
- 244000019459 Cynara cardunculus Species 0.000 description 2
- 235000019106 Cynara scolymus Nutrition 0.000 description 2
- 229920001353 Dextrin Polymers 0.000 description 2
- 239000004375 Dextrin Substances 0.000 description 2
- 241001632410 Eleutherococcus senticosus Species 0.000 description 2
- 239000001512 FEMA 4601 Substances 0.000 description 2
- 229930091371 Fructose Natural products 0.000 description 2
- 239000005715 Fructose Substances 0.000 description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 239000004378 Glycyrrhizin Substances 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 2
- 240000000249 Morus alba Species 0.000 description 2
- 235000008708 Morus alba Nutrition 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- RJECHNNFRHZQKU-UHFFFAOYSA-N Oelsaeurecholesterylester Natural products C12CCC3(C)C(C(C)CCCC(C)C)CCC3C2CC=C2C1(C)CCC(OC(=O)CCCCCCCC=CCCCCCCCC)C2 RJECHNNFRHZQKU-UHFFFAOYSA-N 0.000 description 2
- HELXLJCILKEWJH-SEAGSNCFSA-N Rebaudioside A Natural products O=C(O[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@]1(C)[C@@H]2[C@](C)([C@H]3[C@@]4(CC(=C)[C@@](O[C@H]5[C@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@H](O)[C@@H](CO)O5)(C4)CC3)CC2)CCC1 HELXLJCILKEWJH-SEAGSNCFSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 108010055297 Sterol Esterase Proteins 0.000 description 2
- 102000000019 Sterol Esterase Human genes 0.000 description 2
- 244000228451 Stevia rebaudiana Species 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 235000016520 artichoke thistle Nutrition 0.000 description 2
- 239000000605 aspartame Substances 0.000 description 2
- 235000010357 aspartame Nutrition 0.000 description 2
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 2
- 229960003438 aspartame Drugs 0.000 description 2
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 2
- 108010087173 bile salt-stimulated lipase Proteins 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 235000013351 cheese Nutrition 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- RJECHNNFRHZQKU-RMUVNZEASA-N cholesteryl oleate Chemical compound C([C@@H]12)C[C@]3(C)[C@@H]([C@H](C)CCCC(C)C)CC[C@H]3[C@@H]1CC=C1[C@]2(C)CC[C@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)C1 RJECHNNFRHZQKU-RMUVNZEASA-N 0.000 description 2
- 239000003593 chromogenic compound Substances 0.000 description 2
- 229940097362 cyclodextrins Drugs 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- 150000002016 disaccharides Chemical class 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- HELXLJCILKEWJH-UHFFFAOYSA-N entered according to Sigma 01432 Natural products C1CC2C3(C)CCCC(C)(C(=O)OC4C(C(O)C(O)C(CO)O4)O)C3CCC2(C2)CC(=C)C21OC(C1OC2C(C(O)C(O)C(CO)O2)O)OC(CO)C(O)C1OC1OC(CO)C(O)C(O)C1O HELXLJCILKEWJH-UHFFFAOYSA-N 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 235000015203 fruit juice Nutrition 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 2
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 2
- 229960004949 glycyrrhizic acid Drugs 0.000 description 2
- 235000019410 glycyrrhizin Nutrition 0.000 description 2
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 229940041476 lactose 100 mg Drugs 0.000 description 2
- 239000012669 liquid formulation Substances 0.000 description 2
- 150000002772 monosaccharides Chemical class 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- AHLBNYSZXLDEJQ-FWEHEUNISA-N orlistat Chemical compound CCCCCCCCCCC[C@H](OC(=O)[C@H](CC(C)C)NC=O)C[C@@H]1OC(=O)[C@H]1CCCCCC AHLBNYSZXLDEJQ-FWEHEUNISA-N 0.000 description 2
- 229960001243 orlistat Drugs 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 2
- 235000019203 rebaudioside A Nutrition 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 235000019204 saccharin Nutrition 0.000 description 2
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 2
- 229940081974 saccharin Drugs 0.000 description 2
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 2
- 235000015067 sauces Nutrition 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 229960002920 sorbitol Drugs 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 108090001008 Avidin Proteins 0.000 description 1
- 240000008574 Capsicum frutescens Species 0.000 description 1
- 235000002568 Capsicum frutescens Nutrition 0.000 description 1
- 235000005979 Citrus limon Nutrition 0.000 description 1
- 244000131522 Citrus pyriformis Species 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 239000004278 EU approved seasoning Substances 0.000 description 1
- 241000257465 Echinoidea Species 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 108090000371 Esterases Proteins 0.000 description 1
- 241000510609 Ferula Species 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 108010028554 LDL Cholesterol Proteins 0.000 description 1
- 238000008214 LDL Cholesterol Methods 0.000 description 1
- 108090001060 Lipase Proteins 0.000 description 1
- 239000004367 Lipase Substances 0.000 description 1
- 102000004882 Lipase Human genes 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- 241000237536 Mytilus edulis Species 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- 235000004727 Opuntia ficus indica Nutrition 0.000 description 1
- 240000009297 Opuntia ficus-indica Species 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 240000003296 Petasites japonicus Species 0.000 description 1
- 241000223960 Plasmodium falciparum Species 0.000 description 1
- 240000001462 Pleurotus ostreatus Species 0.000 description 1
- 235000001603 Pleurotus ostreatus Nutrition 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 229930003451 Vitamin B1 Natural products 0.000 description 1
- 229930003779 Vitamin B12 Natural products 0.000 description 1
- 229930003471 Vitamin B2 Natural products 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000001315 anti-hyperlipaemic effect Effects 0.000 description 1
- 230000001399 anti-metabolic effect Effects 0.000 description 1
- 239000006286 aqueous extract Substances 0.000 description 1
- 235000008452 baby food Nutrition 0.000 description 1
- 235000013527 bean curd Nutrition 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 229960002079 calcium pantothenate Drugs 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 210000003022 colostrum Anatomy 0.000 description 1
- 235000021277 colostrum Nutrition 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 239000010779 crude oil Substances 0.000 description 1
- 235000015140 cultured milk Nutrition 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000013367 dietary fats Nutrition 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 239000000469 ethanolic extract Substances 0.000 description 1
- 238000013210 evaluation model Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 229960000815 ezetimibe Drugs 0.000 description 1
- OLNTVTPDXPETLC-XPWALMASSA-N ezetimibe Chemical compound N1([C@@H]([C@H](C1=O)CC[C@H](O)C=1C=CC(F)=CC=1)C=1C=CC(O)=CC=1)C1=CC=C(F)C=C1 OLNTVTPDXPETLC-XPWALMASSA-N 0.000 description 1
- 235000019985 fermented beverage Nutrition 0.000 description 1
- 239000011790 ferrous sulphate Substances 0.000 description 1
- 235000003891 ferrous sulphate Nutrition 0.000 description 1
- 235000013332 fish product Nutrition 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 235000001497 healthy food Nutrition 0.000 description 1
- 208000027700 hepatic dysfunction Diseases 0.000 description 1
- 235000009200 high fat diet Nutrition 0.000 description 1
- 238000007602 hot air drying Methods 0.000 description 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 1
- 229910000359 iron(II) sulfate Inorganic materials 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 235000021109 kimchi Nutrition 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 229940040461 lipase Drugs 0.000 description 1
- 235000019421 lipase Nutrition 0.000 description 1
- 235000019626 lipase activity Nutrition 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 235000013622 meat product Nutrition 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 235000020638 mussel Nutrition 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001508 potassium citrate Substances 0.000 description 1
- 229960002635 potassium citrate Drugs 0.000 description 1
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 description 1
- 235000011082 potassium citrates Nutrition 0.000 description 1
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 1
- 230000009103 reabsorption Effects 0.000 description 1
- 235000021067 refined food Nutrition 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 229960000342 retinol acetate Drugs 0.000 description 1
- 235000019173 retinyl acetate Nutrition 0.000 description 1
- 239000011770 retinyl acetate Substances 0.000 description 1
- QGNJRVVDBSJHIZ-QHLGVNSISA-N retinyl acetate Chemical compound CC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C QGNJRVVDBSJHIZ-QHLGVNSISA-N 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 235000013555 soy sauce Nutrition 0.000 description 1
- 235000015096 spirit Nutrition 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008227 sterile water for injection Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 235000019163 vitamin B12 Nutrition 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- 235000019164 vitamin B2 Nutrition 0.000 description 1
- 239000011716 vitamin B2 Substances 0.000 description 1
- 235000019158 vitamin B6 Nutrition 0.000 description 1
- 239000011726 vitamin B6 Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 229940011671 vitamin b6 Drugs 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/326—Foods, ingredients or supplements having a functional effect on health having effect on cardiovascular health
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/3262—Foods, ingredients or supplements having a functional effect on health having an effect on blood cholesterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Mycology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicinal Preparation (AREA)
Abstract
본 발명은 아위버섯의 물 추출물을 유효성분으로 함유하는 고지혈증의 예방 또는 치료용 조성물 및 이를 포함하는 건강 기능성 식품에 관한 것으로, 아위버섯의 물 추출물은 콜레스테롤 에스터레이즈의 활성 및 중성지방 흡수 저해능이 에탄올 추출물에 비하여 탁월하게 뛰어난 효과가 있다.The present invention relates to a composition for preventing or treating hyperlipidemia, which comprises water extract of Astragalus mushroom as an active ingredient, and a health functional food containing the same, wherein the water extract of Astragalus mushroom has an activity of raising cholesterol ester and an ability of neutral fat absorption, It has an excellent effect over the extract.
Description
본 발명은 고지혈증 예방 또는 치료를 목적으로 사용될 수 있는 아위버섯의 물 추출물을 포함하는 약학적 조성물 및 건강 보조식품 조성물에 관한 것이다.The present invention relates to a pharmaceutical composition comprising a water extract of Astragalus mushroom, which can be used for prevention or treatment of hyperlipidemia, and a health supplement food composition.
고지혈증은 혈액 속에 지방성분이 높은 상태를 말한다. 일반적으로 총 콜레스테롤이 240mg/dl을 넘거나 중성지방이 200mg/dl이상일 때 고지혈증이라 한다. 고지혈증은 콜레스테롤 덩어리가 혈관을 막고 혈액순환을 저해해 고혈압, 심근경색, 뇌졸증을 유발하는 주요 원인으로 알려져 있다. 우리나라의 고지혈증 환자수 또한 꾸준히 증가하고 있으며, 세계적으로 고지혈증 환자의 증가가 급증하고 있어 더 많은 고지혈증 환자의 증가를 초래할 것으로 예상된다. 이에 고지혈증의 치료 및 예방법, 처방법에 대한 많은 보고들이 제시되고 있다.
Hyperlipidemia refers to a state of high fat in blood. Generally, hyperlipidemia is defined as total cholesterol greater than 240 mg / dl or triglycerides greater than 200 mg / dl. Hyperlipidemia is known to be a major cause of hypertension, myocardial infarction and stroke due to cholesterol cholesterol blocking blood vessels and inhibiting blood circulation. The number of patients with hyperlipidemia has also been increasing steadily, and the number of patients with hyperlipidemia is increasing rapidly, which is expected to lead to an increase in the number of patients with hyperlipidemia. There are many reports on the treatment and prevention of hyperlipidemia and prescription methods.
고지혈증의 발생 원인은 유전적인 요인으로 인한 대사장애도 있지만 과도한 열량의 식사와 운동 부족으로 촉발되는 비만과 같은 다른 원인에서도 혈액 내 콜로스테롤이 축적되어 발생한다(Bray GA, Popkin BM.: Dietary fat intake dose affect obesity. Am. J Clin. Nutr 68 : 1157-1173 (1998)). 특히 서구화된 식단으로 인한 고지방 식이의 섭취 증가가 고지혈증의 주된 이유로 여겨지고 있다. 현재 전세계적으로 고지혈증의 예방 또는 치료를 위해 콜레스테롤 흡수 저해제 등 후보 효능물질에 대한 개발이 활발하게 이루어지고 있으며, 그에 따라 항고지혈증 효능평가모델에 대한 관심도 증대되고 있다.
The cause of hyperlipidemia is due to genetic factors and metabolic disturbances, but colostrums accumulate in the blood even in other causes such as excessive calorie meals and obesity triggered by lack of exercise (Bray GA, Popkin BM .: Dietary fat intake dose affect obesity. Am. J Clin. Nutr 68: 1157-1173 (1998)). In particular, increased intake of high-fat diets due to westernized diets is believed to be the main reason for hyperlipemia. At present, there are active development of candidate efficacies such as cholesterol absorption inhibitors for the prevention or treatment of hyperlipidemia worldwide, and accordingly, there is a growing interest in an evaluation model of antihyperlipidemic efficacy.
현재 고지혈증 치료약물은 스타틴(statin)계열의 약물이 널리 사용되어 지고 있다. 이 계열의 약은 HMG-CoA환원효소 억제제로 콜레스테롤 합성 억제 및 혈중 LDL-콜레스테롤를 저하시키는 효과가 있다. 이 외에도 에제티미브(ezetimibe), 니아신(niacin) 그리고 피브레이트(bibrate)제제등이 주로 사용되어 지고 있으나 약물 투여시 드물게 근육통, 변비 내지는 소화장애 및 간기능 장애가 발생하는 부작용이 생길 우려가 있다.
Currently, statin drugs are widely used for the treatment of hyperlipidemia. This class of drugs is an HMG-CoA reductase inhibitor that has the effect of inhibiting cholesterol synthesis and lowering blood LDL-cholesterol. In addition, ezetimibe, niacin and bibrate preparations are mainly used. However, there is a possibility that side effects such as myalgia, constipation or digestive disorder and hepatic dysfunction are rarely observed when the drug is administered.
한편, 버섯류는 전 세계적으로 약 1만 여종이 보고되어 있으며 식용 및 약용가치가 높아 미생물 유용자원으로의 확보를 위해, 유럽, 미국, 일본 등의 선진국에서 많은 연구가 이루어지고 있다. 특히 버섯류가 생산하는 생리활성물질은 부작용이 적어 독성면에서 안전하고 인체 내 면역계의 기능 조절, 항암효과, 신진대사 조절 등의 다양한 기능을 가지고 있다는 많은 연구 결과가 보고되고 있다.
On the other hand, about 10,000 kinds of mushrooms are reported all over the world, and many studies have been conducted in developed countries such as Europe, America, and Japan in order to secure useful resources for microorganisms because of high value of edible and medicinal products. In particular, many studies have reported that physiologically active substances produced by mushrooms have various side effects such as toxicity, safe function of the immune system in the human body, anti-cancer effect, and metabolic regulation.
본 발명의 발명자들은 생체 내 부작용이 거의 나타나지 않고, 체내 콜레스테롤 흡수를 저해하여 고지혈증 개선 효과를 가지는 천연물질에 대해 연구를 거듭하여 본 발명을 착수하였다.
The present inventors have undertaken the present invention by repeatedly studying natural substances having little or no in vivo side effects and inhibiting the absorption of cholesterol in the body and having an effect of improving hyperlipemia.
상기 아위버섯의 학명은 Pleurotus eryngii var. ferulea (Pf : P.ferulea)으로 새송이버섯의 변종이다. 영어명칭은 페룰라 오이스터 머쉬룸(Ferula Oyster Mushroom)으로, 해석하면 아위나무 느타리버섯이다. 중국에서는 백령측이(白靈側耳)라고 부른다. 중국의 건조지대인 신강지방의 아위 나무에서 야생하는 것으로 생장온도는 8~20도씨의 중온으로 우리나라의 봄, 가을 재배에 적합하다.The scientific name of the above mushroom is Pleurotus eryngii var. ferulea (Pf: P.ferulea) is a variant of the mushroom. The English name is Ferula Oyster Mushroom, which is interpreted as a mushroom of Aiuchi. In China, Baekryeong side (白 霊 side ears) is called. It is wild in the arid tree of Xinjiang province, which is a dry region of China. It is suitable for growing in spring and autumn in Korea because it is medium temperature of 8 ~ 20 degrees.
중국과 중앙아시아에서 자생하는 아위버섯은 막힌데를 풀어주고 기침과 염증을 해소시키고 위장 질환에 효험이 있는 약용식물로 알려져 있고 한의학 서적 등에 인체의 독소를 배출하고 기침을 멎게 하며 염증을 해소시키고 산부인과 계통 질환에도 효과가 있다고 소개된 고기능성 버섯이다.It is known as a medicinal plant which is effective in gastrointestinal diseases, it releases coughs and inflammation, releases toxins in human body medicine books, stops coughing, relieves inflammation, It is a highly functional mushroom that has been shown to be effective in systemic diseases.
본 발명의 발명자들은 스타틴(statin)과 같은 약물을 대체할 만한 천연물질로, 소장에서 콜레스테롤 및 중성지방의 재흡수를 억제 하거나 혈중 콜레스테롤을 감소시키는 저해제에 대한 연구를 거듭 하던 중, 아위버섯의 추출물, 특히 아위버섯의 물 추출물이 혈중 콜레스테롤 및 중성지방의 흡수를 효과적으로 저해하는 것을 확인하고 본 발명을 완성하였다.The inventors of the present invention have intensively studied the inhibitors that inhibit the reabsorption of cholesterol and triglyceride in the small intestine or reduce the cholesterol in the blood while substituting drugs such as statin, , Especially the water extract of Astragalus mushroom, effectively inhibited the absorption of cholesterol and triglyceride in the blood and completed the present invention.
따라서, 본 발명은 생체 내 부작용이 거의 나타나지 않고, 체내 콜레스테롤 및 중성지방 흡수를 저해용 물을 포함하는 조성물 및 이를 유효성분으로 함유하는 예방 또는 치료용 의학적 조성물 및 건강 기능성 식품을 제공하는데 있다.Accordingly, it is an object of the present invention to provide a composition containing a substance for inhibiting cholesterol and triglyceride absorption in the body, which hardly shows any side effects in vivo, and a medical composition and a health functional food containing the active ingredient as a preventive or therapeutic composition.
본 발명의 상기 목적은 아위버섯의 물 추출물을 수득하고 이를 공시 재료로 하여 고지혈증 개선 효과를 검증하고 이를 평가함으로써 달성하였다.The above object of the present invention is attained by obtaining water extract of Astragalus mushroom and using it as a test material to verify and evaluate the effect of improving hyperlipemia.
본 발명의 아위버섯의 물 추출물을 유효 성분으로 포함하는 조성물은 체내 콜레스테롤 및 중성지방 흡수를 저해함으로써 고지혈증의 예방 또는 치료 용도로 유용하게 사용될 수 있는 뛰어난 효과가 있다.The composition comprising the water extract of Astaxantha mushroom as an active ingredient of the present invention has an excellent effect that can be effectively used for preventing or treating hyperlipemia by inhibiting the absorption of cholesterol and triglyceride in the body.
도1은 본 발명의 실시예와 비교예의 아위버섯의 추출물의 CEL 활성 저해 효능을 비교하여 나타낸 그래프이다.
도 2는 본 발명의 실시예에 따른 아위버섯 물 추추출물의 농도에 따른 CEL 활성을 비교하여 나타낸 그래프이다.
도 3은 본 발명의 실시예에 따른 아위버섯 물 추출물의 농도에 따른 TGL 활성을 비교하여 나타낸 그래프이다.
도 4는 본 발명의 실시예에 따른 아위버섯의 물 추출물과 종래의 지방저해제인 orlistat의 소화관으로부터 혈액으로의 콜레스테롤 흡수량을 비교하여 나타낸 그래프이다.FIG. 1 is a graph comparing the CEL activity inhibitory effects of the extract of Astragalus mushroom of the examples of the present invention and the comparative example.
FIG. 2 is a graph comparing CEL activities according to the concentration of the water extract of P. japonicus according to an embodiment of the present invention. FIG.
FIG. 3 is a graph showing a comparison of TGL activity according to the concentration of the water extract of avi mushroom according to an embodiment of the present invention.
FIG. 4 is a graph comparing the amounts of cholesterol absorption from blood of a digestive tract of orlistat, a water extract of Astragalus mushroom and a conventional fat inhibitor, according to an embodiment of the present invention.
아위버섯의 물 추출물은 통상의 식물 추출물의 제조방법에 따라 제조된 것일 수 있다. 가장 바람직하게는 상기 아위버섯을 15℃의 냉온 건조한 후에 분쇄한 다음 잔사를 제거하고, 물 100mL 당 상기 분쇄물 0.1 내지 20g을 첨가하여, 가장 바람직하게는 추출 용매 100 mL 당 분쇄물 1 내지 5 g을 첨가하여 추출한다. 40℃이상의 열풍 건조는 바람직하지 않았다. 또, 아위버섯 분쇄물의 함량이 추출 용매 대비하여 지나치게 적은 경우 아위버섯의 콜레스테롤 흡수 효과가 충분히 이루어 지지 않아 바람직하지 않고, 추출 용매의 양 대비 지나치게 많은 경우 함량 증가에 따른 효과의 증대는 크지 않은 반면 생산 비용이 증가하므로 생산성 측면에서 바람직하지 않다.
The water extract of Astragalus mushroom may be one prepared by a conventional method for producing a plant extract. Most preferably, the above dried mushroom is cooled and dried at a temperature of 15 캜, followed by pulverization. Then, the residue is removed, and 0.1 to 20 g of the pulverized product per 100 ml of water is added. Most preferably, 1 to 5 g of pulverized product per 100 ml of the extraction solvent And then extracted. Hot air drying at 40 占 폚 or higher was not preferred. In addition, when the content of crushed mulberry crumbs is too small compared to the extraction solvent, the cholesterol absorption effect of mugwort mushroom is not sufficient, and when the amount of the crushed mulberry crumbs is excessively large relative to the amount of the extraction solvent, The cost is increased, which is not preferable from the viewpoint of productivity.
아위버섯의 추출 조건은 바람직하게 아위버섯을 추출 용매인 물과 혼합한 후, 20 내지 60℃의 온도에서, 12 내지 36 시간 동안, 가장 바람직하게는 30 내지 40℃의 온도에서, 20 내지 24 시간 동안 추출하여야 한다.
The extracting conditions of the mushroom are preferably mixed with water as an extracting solvent and then heated at a temperature of 20 to 60 DEG C for 12 to 36 hours, most preferably at a temperature of 30 to 40 DEG C for 20 to 24 hours .
20℃이하의 낮은 온도 조건에서 추출하는 경우, 유효 추출 성분의 추출을 위해서 긴 시간이 요구되며, 60℃이상의 고온 조건에서 추출하는 경우, 활성이 떨어져 바람직하지 않았다. 특히, 100℃에서 15분이상 열 수추출한 수추출물도 활성이 없으므로 사용할 수 없었다.
When extracting at a low temperature of 20 ° C or less, a long time is required for extracting the effective extract components. When extracting at a high temperature of 60 ° C or higher, the activity is poor and it is not preferable. In particular, water extracts extracted with heat at 100 ° C for 15 minutes or more were not available because of no activity.
그리고, 추출 시간을 12시간 이하 짧게 하는 경우, 추출되는 유효 성분의 농도가 낮고, 36시간 이상 긴 시간 동안 추출하는 경우, 추출 시간의 증가에 따른 추출 유효 성분의 농도 증가가 미미하여 생산성 측면에서 바람직하지 않았다.
When the extraction time is shortened to 12 hours or less, the concentration of the effective ingredient to be extracted is low, and when the extraction is performed for a long time longer than 36 hours, the increase in concentration of the extraction effective ingredient with increasing extraction time is insufficient, I did.
그리고, 상기와 같은 방법으로 추출한 아위버섯의 물 추출액은 여과포 등으로 여과한 후, 여액을 원심분리시켜 침전물을 제거시킨 다음, 감압 농축 또는 농축 한 후, 동결 건조하여 사용하는 것이 바람직하였다.
The water extract of the sea tangle mushroom extracted by the above method is preferably filtered using a filter or the like, and then the filtrate is centrifuged to remove the precipitate and then concentrated or concentrated under reduced pressure, followed by lyophilization.
한편, 상술한 구현예의 고지혈증의 치료 또는 예방 조성물 중 유효성분인 아위버섯의 물 추출물의 함량은 바람직하게는 0.01 내지 30 중량%이다. 유효 성분인 아위버섯의 물 추출물의 함량이 0.01 중량% 미만인 경우에는, 체내 콜레스테롤 흡수 저해 효과가 미미하며, 30 중량%를 초과하는 경우에는 함량 증가에 따른 저해 활성 증가 효과가 미미하여 경제적이지 못하다. 바람직하기는 조성물 내에 아위버섯의 물 추출물의 함량은 0.001 내지 50 중량%, 가장 바람직하게는 0.1 내지 30 중량%이었다.
On the other hand, the content of the water extract of avium mushroom as an active ingredient in the above-mentioned embodiment of the composition for treating or preventing hyperlipidemia is preferably 0.01 to 30% by weight. When the content of the water extract of the active ingredient, mugwort, is less than 0.01% by weight, the effect of inhibiting cholesterol absorption in the body is insignificant. When the content is more than 30% by weight, the effect of increasing the inhibitory activity is insufficient. Preferably, the content of the water extract of sea urchin mushroom in the composition is 0.001 to 50% by weight, most preferably 0.1 to 30% by weight.
본 발명은 구현예에 따라 상기 조성물에 포함된 아위버섯의 물 추출물을 유효성분으로 포함하는 고지혈증의 예방 또는 치료용 의약품을 제공한다. 이와 같은 아위버섯의 물 추출물을 유효성분으로 포함하는 의약품은 그 제조에 통상적으로 사용하는 적절한 담체, 부형제 및 희석제를 더욱 포함할 수 있다.
The present invention provides a medicament for preventing or treating hyperlipidemia, which comprises, as an active ingredient, a water extract of Astragalus mushroom contained in the composition according to an embodiment. Such a medicament containing the water extract of Astragalus mushroom as an active ingredient may further contain suitable carriers, excipients and diluents conventionally used in the production thereof.
본 발명의 아위버섯의 물 추출물을 유효성분으로 포함하는 의약품에 포함될 수 있는 담체, 부형제 및 희석제로는 락토스, 덱스트로스, 수크로스, 솔비톨, 만니톨, 자일리톨, 에리스리톨, 말티톨, 전분, 아카시아 고무, 알지네이트, 젤라틴, 칼슘 포스페이트, 칼슘 실리케이트, 셀룰로오스, 메틸 셀룰로오스, 미정질 셀룰로오스, 폴리비닐 피롤리돈, 물, 메틸히드록시벤조에이트, 프로필히드록시벤조에이트, 탈크, 마그네슘 스테아레이트 및 광물유를 들 수 있다.
Examples of carriers, excipients, and diluents that can be included in the medicament containing the water extract of the present invention as an active ingredient of the present invention include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, , Gelatin, calcium phosphate, calcium silicate, cellulose, methylcellulose, microcrystalline cellulose, polyvinylpyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil.
본 발명의 아위버섯의 물 추출물을 유효성분으로 포함하는 의약품은 각각 통상의 방법에 따라 산제, 과립제, 정제, 현탁제, 에멀젼, 시럽 등의 경구형 제형물로 사용될 수 있다. The medicinal product containing the water extract of Astaxantha mushroom of the present invention as an active ingredient can be used as oral formulations such as powders, granules, tablets, suspensions, emulsions and syrups according to a conventional method.
상기 경구형 제형물은 경구 투여를 위한 고형제제와 액상제제를 포함하는 의미이며, 경구투여를 위한 고형제제에는 정제, 환제, 산제, 과립제, 캡슐제 등이 포함될 수 있으며, 이러한 고형제제는 상기 추출물에 적어도 하나 이상의 부형제 예를 들면, 전분, 칼슘카보네이트(calcium carbonate), 수크로스(sucrose) 또는 락토오스(lactose), 젤라틴 등을 섞어 조제될 수 있다. The oral formulations are meant to include solid and liquid formulations for oral administration and solid formulations for oral administration may include tablets, pills, powders, granules, capsules and the like, For example, starch, calcium carbonate, sucrose or lactose, gelatin and the like in combination with at least one excipient.
또한, 단순한 부형제 이외에 마그네슘 스테아레이트, 탈크 같은 윤활제들도 사용될 수 있다. 경구를 위한 액상 제제로는 현탁제, 내용액제, 유제, 시럼제 등이 해당되는데, 흔히 사용되는 단순희석제인 물, 리퀴드 파라핀 이외에 여러가지 부형제 예를 들면, 습윤제, 감미제, 방향제, 보존제 등이 포함될 수 있다.
In addition to simple excipients, lubricants such as magnesium stearate and talc may also be used. Examples of liquid formulations for oral use include suspensions, solutions, emulsions, and syrups. In addition to commonly used simple diluents such as water and liquid paraffin, various excipients such as wetting agents, sweetening agents, have.
본 발명의 아위버섯의 물 추출물을 함유하는 약학적 조성물의 바람직한 투여량은 상태 및 체중, 질병의 정도, 약물형태, 투여경로 및 기간에 따라 다르지만, 당업자에 의해 적절하게 선택될 수 있다. 바람직하게는 본 발명의 아위버섯의 물 추출물을 유효성분으로 함유하는 의약품은 아위버섯의 물 추출물의 양을 기준으로 1일 성인기준(60kg체중) 0.0001 내지 100mg/kg으로, 보다 효과적이기 위해서는 0.01 내지 10mg/kg으로 투여하는 것이 바람직하다. 투여횟수는 1일에 1회 투여할 수 있고, 수회 나누어 투여할 수도 있다. 상기 투여량과 투여횟수는 어떠한 면으로든 본 발명의 범위를 한정하는 것은 아니다.
The preferred dosage of the pharmaceutical composition containing the water extract of Astragalus membranes of the present invention varies depending on the condition and body weight, degree of disease, drug form, route of administration, and duration, but can be appropriately selected by those skilled in the art. Preferably, the medicinal product containing the water extract of Astragalus membranaceus of the present invention as an active ingredient is administered at a daily adult standard (60 kg body weight) of 0.0001 to 100 mg / kg on the basis of the amount of water extract of Astragalus mushroom, 10 mg / kg. The number of administrations may be administered once a day or divided into several administrations. The dose and the number of administrations do not limit the scope of the present invention in any aspect.
본 발명의 다른 구현 예에 따라, 아위버섯의 물 추출물을 유효성분으로 포함하는 고지혈증의 개선용 건강 기능성 식품을 제공한다. 본 명세서에서 ‘건강 기능성 식품’이라 함은 영양소를 한 가지 또는 그 이상 함유하고 있는 천연물 또는 가공품을 의미하며, 바람직하게는 어느 정도의 가공 공정을 거쳐 직접 먹을 수 있는 상태가 된 것을 의미한다.
According to another embodiment of the present invention, there is provided a health functional food for improving hyperlipidemia comprising an aqueous extract of Astragalus mushroom as an active ingredient. In the present specification, the term 'health functional food' means a natural product or a processed product containing one or more nutrients, preferably a state of being able to be directly eaten through a certain processing step.
본 발명의 아위버섯의 물 추출물을 첨가할 수 있는 건강 기능성 식품으로는 예를 들어, 각종 식품류, 음료, 껌, 차, 비타민 복합제 등이 있다. 추가로, 본 발명에서 식품에는 특수영양식품(예, 조제유류, 영,유아식 등), 식육가공품, 어육제품, 두부류, 묵류, 면류(예, 라면류, 국수류 등), 건강보조식품, 조미식품(예, 간장, 된장, 고추장, 혼합장 등), 소스류, 과자류(예, 스넥류), 유가공품(예, 발효유, 치즈 등), 기타 가공식품, 김치, 절임식품(각종 김치류, 장아찌 등), 음료(예, 과실,채소류 음료, 두유류, 발효음료류 등), 천연조미료(예, 라면 스프 등)을 포함하나 이에 한정되지 않는다. 상기 식품, 음료 또는 식품첨가제는 통상의 제조방법으로 제조될 수 있다. Examples of the health functional food to which the water extract of the present invention can be added include various foods, beverages, gums, tea, vitamin complex, and the like. In addition, in the present invention, the food may contain special nutritional foods (e.g., crude oil, spirits, infant food, etc.), meat products, fish products, tofu, jelly, noodles (Such as soy sauce, soybean paste, hot pepper paste, mixed sauce), sauces, confectionery (eg snacks), dairy products (eg fermented milk, cheese), other processed foods, kimchi, pickled foods But are not limited to, fruits, vegetables, beverages, fermented beverages, etc.), natural seasonings (e.g., ramen soup, etc.). The food, beverage or food additive may be prepared by a conventional production method.
본 명세서에서, 기능성 식품이란 식품에 물리적, 생화학적, 생물공학적 수법 등을 이용하여 해당 식품의 기능을 특정 목적에 작용, 발현하도록 부가가치를 부여한 식품군이나 식품 조성이 갖는 생체방어리듬조절, 질병방지와 회복 등에 관한 체조절기능을 생체에 대하여 충분히 발현하도록 설계하여 가공한 식품을 의미한다. 상기 기능성 식품에는 식품학적으로 허용 가능한 식품 보조 첨가제를 포함할 수 있으며, 기능성 식품의 제조에 통상적으로 사용되는 적절한 담체, 부형제 및 희석제를 더욱 포함할 수 있다.
In the present specification, the functional food refers to a food group which is imparted with added value to function and express the function of the food by using physical, biochemical, biotechnological techniques, etc., Means a food which is processed and designed so that the body control function related to restoration and the like is sufficiently expressed to the living body. The functional food may include a food-acceptable food-aid additive, and may further comprise suitable carriers, excipients and diluents conventionally used in the production of functional foods.
본 명세서에서, 음료란 갈증을 해소하거나 맛을 즐기기 위하여 마시는 것의 총칭을 의미하며 기능성 음료를 포함하는 의도이다. 상기 음료는 지시된 비율로 필수 성분으로서 상기 아위버섯의 물 추출물을 유효성분으로 포함하는 것 외에 다른 성분에는 특별한 제한이 없으며 통상의 음료와 같이 여러 가지 향미제 또는 천연 탄수화물 등을 추가 성분으로서 함유할 수 있다. 상기의 천연 탄수화물의 예는 모노사카라이드, 예를 들어 포도당, 과당 등 디사카라이드, 예를 들어 말토스, 수크로스 등 및 폴리사카라이드, 예를 들어 덱스트린, 시클로덱스트린 등과 같은 통상적인 당, 및 자일리톨, 소르비톨, 에리트리톨 등의 당알콜이다. 상기한 것 이외의 향미제로서 천연 향미제(타우마틴, 스테비아 추출물(예를 들어 레바우디오시드 A, 글리시르히진 등) 및 합성 향미제(사카린, 아스파르탐 등)를 유리하게 사용할 수 있다. 상기 천연 탄수화물의 비율은 본 발명의 조성물 100mL 당 일반적으로 약 1 내지 20g, 바람직하게는 5 내지 12g일 수 있다. 그밖에 본 발명의 조성물은 천연 과일 주스, 과일 쥬스 음료, 야채 음료의 제조를 위한 과육을 추가로 함유할 수 있다.
In the present specification, beverage means a generic term for drinking or enjoying a taste and is intended to include a functional beverage. The beverage is not limited to any particular ingredient except that it contains the water extract of the mussel as an active ingredient as an essential ingredient at the indicated ratio and may contain various flavors or natural carbohydrates as an additional ingredient . Examples of such natural carbohydrates include monosaccharides such as disaccharides such as glucose and fructose such as maltose, sucrose and the like and polysaccharides such as dextrins, cyclodextrins and the like, and Xylitol, sorbitol, and erythritol. Natural flavors (tau martin, stevia extract (e.g., rebaudioside A, glycyrrhizin, etc.) and synthetic flavors (saccharin, aspartame, etc.) can be advantageously used as flavors other than those described above The ratio of the natural carbohydrate may be generally about 1 to 20 g, preferably 5 to 12 g, per 100 mL of the composition of the present invention. In addition, the composition of the present invention may be used for the production of natural fruit juice, fruit juice drink, And may further contain flesh.
상기 외에 본 발명의 건강 기능성 식품은 여러 가지 영양제, 비타민, 광물(전해질), 합성 풍미제 및 천연 풍미제 등의 풍미제, 착색제 및 중진제(치즈, 초콜릿 등), 펙트산 및 그의 염, 알긴산 및 그의 염, 유기산, 보호성 콜로이드 증점제, pH 조절제, 안정화제, 방부제, 글리세린, 물, 탄산 음료에 사용되는 탄산화제 등을 함유할 수 있다. 이러한 성분을 독립적으로 또는 조합하여 사용할 수 있다. 이러한 첨가제의 비율은 그렇게 중요하지 않지만, 본 발명의 아위버섯의 물 추출물 100 중량부 당 0 내지 20 중량부 범위에서 선택될 수 있다.
In addition to the above, the health functional food of the present invention may contain various kinds of nutrients, vitamins, minerals (electrolytes), flavors such as synthetic flavors and natural flavors, colorants and heavies (cheese, chocolate etc.), pectic acid and its salts, And salts thereof, organic acids, protective colloid thickeners, pH adjusting agents, stabilizers, preservatives, glycerin, water, carbonating agents used in carbonated drinks, and the like. These components can be used independently or in combination. The proportion of such additives is not so critical, but may be selected in the range of 0 to 20 parts by weight per 100 parts by weight of the water extract of the present invention.
본 명세서에서 기능성 음료란 음료에 물리적, 생화학적, 생물공학적 수법 등을 이용하여 해당 음료의 기능을 특정 목적에 작용, 발현하도록 부가가치를 부여한 음료 군이나 음료 조성이 갖는 생체방어리듬조절, 질병방지와 회복 등에 관한 체조절기능을 생체에 대하여 충분히 발현하도록 설계하여 가공한 음료를 의미한다.
In the present specification, functional beverages are used to control the bio-defense rhythm of the beverage group or beverage composition to which the added value is imparted so that the function of the beverage functions for a specific purpose by using physical, biochemical, biotechnological techniques, Means a beverage which has been designed so that the body control function related to restoration and the like is sufficiently expressed in the living body.
상기 기능성음료는 지시된 비율로 필수 성분으로서 본 발명의 아위버섯의 물 추출물을 함유하는 외에는 다른 성분에는 특별한 제한이 없으며 통상의 음료와 같이 여러 가지 향미제 또는 천연 탄수화물 등을 추가 성분으로서 함유할 수 있다. 상기 천연 탄수화물의 예는 모노사카라이드, 예를 들어 포도당, 과당 등 디사카라이드, 예를 들어 말토스, 수크로스 등 및 폴리사카라이드, 예를 들어 덱스트린, 시클로덱스트린 등과 같은 통상적인 당, 및 자일리톨, 소르비톨, 에리트리톨 등의 당알콜이다. 상기한 것 이외의 향미제로서 천연 향미제(타우마틴, 스테비아 추출물(예를 들어 레바우디오시드 A, 글리시르히진 등) 및 합성 향미제(사카린, 아스파르탐 등)를 유리하게 사용할 수 있다. 상기 천연 탄수화물의 비율은 본 발명의 조성물 100mL 당 일반적으로 약 1 내지 20 g, 바람직하게는 5 내지 12 g이다.The functional beverage is not particularly limited to the other ingredients except that it contains the water extract of the present invention as an essential ingredient in the indicated ratios and may contain various flavors or natural carbohydrates as an additional ingredient such as ordinary drinks have. Examples of such natural carbohydrates include monosaccharides such as disaccharides such as glucose and fructose such as maltose, sucrose and the like and polysaccharides such as dextrins, cyclodextrins and the like, and xylitol , Sorbitol, and erythritol. Natural flavors (tau martin, stevia extract (e.g., rebaudioside A, glycyrrhizin, etc.) and synthetic flavors (saccharin, aspartame, etc.) can be advantageously used as flavors other than those described above The ratio of the natural carbohydrate is generally about 1 to 20 g, preferably 5 to 12 g per 100 mL of the composition of the present invention.
또한, 고지혈증의 개선 또는 예방을 목적으로 하는 건강 기능성 식품 에 있어서, 상기 추출물의 양은 전체 식품 중량의 0.01 내지 15 중량%로 포함할 수 있으며, 음료 조성물은 100 mL를 기준으로 0.02 내지 5 g, 바람직하게는 0.3 내지 1g의 비율로 포함할 수 있다.
In addition, in the health functional food for the purpose of improving or preventing hyperlipidemia, the amount of the extract may be 0.01 to 15% by weight of the total food, and the beverage composition may contain 0.02 to 5 g May be contained in a proportion of 0.3 to 1 g.
한편, 본 발명은 또 다른 구현예에 따라 상기와 같은 아위버섯의 물 추출물을 제조하는 방법을 제공한다.According to another embodiment of the present invention, there is provided a method for preparing the above water extract of Astragalus mushroom.
본 발명의 일 구현예에 따른 아위버섯의 물 추출물의 제조 방법은 아위버섯의 분말을 준비하는 단계; 상기 아위버섯 분말을 물과 혼합하는 단계; 및 상기 혼합물을 20 내지 60℃ 의 온도에서, 12 내지 36 시간 동안 추출하는 단계를 포함한다.
According to an embodiment of the present invention, there is provided a method for preparing a water extract of Acanthopanax senticosus, comprising: preparing powder of Acanthopanax senticosus; Mixing the avid mushroom powder with water; And extracting the mixture at a temperature of 20 to 60 DEG C for 12 to 36 hours.
이하, 본 발명의 구체적인 실시예를 통하여 발명의 구성 및 효과를 보다 상세히 설명하기로 한다. 그러나 하기의 실시예는 발명을 보다 명확하게 이해시키기 위한 것일 뿐이며, 발명의 권리범위가 하기 실시예에 한정되는 것은 아니다.
Hereinafter, the structure and effects of the present invention will be described in more detail with reference to specific examples of the present invention. However, the following examples are only for the purpose of clarifying the invention, and the scope of the invention is not limited to the following examples.
다만, 본 발명을 벗어난 예컨대 아위버섯의 분말은 본 발명자들이 집중하여 반복 실험한 결과, 콜레스테롤 에스터레이즈 활성 저해 효과가 없으므로 본 발명의 권리 범위에 속하지 아니한다 할 것이다.
However, for example, powder of Astragalus mushroom, which is devoid of the present invention, as a result of intensive and repeated experiments conducted by the present inventors, does not have an effect of inhibiting cholesterol ester raising activity, and thus does not fall within the scope of the present invention.
[[ 실시예Example ] ] 아위버섯의Mushroom 물 추출물 준비 Water extract preparation
건조된 아위버섯(Pleurotus eryngii var. ferulea (Pf.)을 시중에서 구입하여 조대분말화한 후 거즈로 된 봉지에 넣고 분말 1g 당, 추출 용매로써 물 50mL를 혼합한 후, 37℃에서 24시간 동안 진탕배양기에추출하였다. 진탕배양기의 상등액을 2500rpm으로 10분 동안 원심 분리한 후 여과한 상등액을 수집하여, 공시재료로 사용하였다.
Dried mushroom (Pleurotus eryngii var. Ferulea (Pf.) Was purchased from the market and coarsely pulverized and put into a bag made of gauze. After mixing 50 ml of water with 1 g of powder as an extraction solvent, The supernatant of the shaking incubator was centrifuged at 2500 rpm for 10 minutes, and the supernatant was collected and used as a labeling material.
[[ 비교예Comparative Example ] ] 아위버섯의Mushroom 물 추출물 준비 Water extract preparation
추출 용매로써 물 50mL대신에 에탄올(99.9% (v/v)) 70% 및 100% 각 100mL 를 사용한 점을 제외하고는 상기 실시예와 동일한 방법으로 65℃이상에서 아위버섯의 에탄올 환류 추출물을 공시재료로 준비하였다.
The ethanol reflux extract of the mushroom was disclosed at 65 ° C or higher in the same manner as in the above example, except that 70% of ethanol (99.9% (v / v)) and 100 mL of 100% Materials were prepared.
<< 실험예1Experimental Example 1 > 본 발명 > Invention 아위버섯Avi mushroom 추출물에 의한 췌장 콜레스테롤 Pancreatic cholesterol by extract 에스터레이즈Esther Reyes 활성 측정 Active measurement
췌장 콜레세테롤 에스터레이즈는 acyl chain을 가지는 기질들을 비 특이적으로 인식하여 acyl chain을 분리하는 역할을 한다. 실시예 및 비교예의 아위버섯 추출물에 의한 췌장 콜레스테롤 에스터레이즈 활성을 측정하기 위하여, 효소로 시그마 케미칼에서 제조된 포오신 판크리틱 콜레스테롤 에스터레이즈를 사용하였다.Pancreatic cholesetester esterase plays a role in recognizing acyl chain - bearing substrates as non - specific and isolating acyl chains. In order to measure the pancreatic cholesterol ester raising activity by the extracts of Opuntia ficus-indica in the examples and the comparative examples, a poison flinic acid cholesterol ester raise made in a sigma chemical as an enzyme was used.
췌장 콜레스테롤 에스터레이즈가 chromo-genic substrate (p-nirophenylbutyrate)을 분해하는 성질을 이용하여 발색 반응을 통해 enzyme의 활성변화를 확인하였다. 효소의 활성 저해 효과는 Microplate reader를 이용하여 405nm의 흡광도의 변화를 통해 측정하고, 추출물 비처리 그룹의 405nm흡광도를 베이스로 하여, 계산하여 %로 나타내었다.Pancreatic cholesterol esterase cleaved the chromo-genic substrate (p-nirophenylbutyrate) and the activity of the enzyme was confirmed by color reaction. The inhibitory effect of the enzyme was measured using a microplate reader at 405 nm and calculated as% based on the absorbance at 405 nm of the extract-untreated group.
실시예 및 비교예의 추출물에 의해 효소의 활성이 어떻게 달라지는지 측정하였고, 그 결과 실시예의 물 추출물이 췌장 콜레스테롤 에스터레이즈 의 활성을 현저하게 저하시키는 것을 확인하였다.The activity of the enzyme was measured by the extracts of Examples and Comparative Examples. As a result, it was confirmed that the water extract of the Example significantly reduced the activity of the pancreatic cholesterol ester raise.
한편, 비교예의 70% 및 100% 에탄올 추출물 시료들에서는 췌장 콜레스테롤 에스터레이즈의 활성을 저해하는 효과가 거의 나타나지 않았다. 실험 결과를 도 1 에 비교하여 간단히 나타내었다.
On the other hand, in the 70% and 100% ethanol extract samples of the comparative example, the effect of inhibiting the activity of pancreatic cholesterol ester raise was hardly observed. The experimental results are briefly shown in comparison with FIG.
<< 실험예2Experimental Example 2 > > 아위버섯Avi mushroom 물 추출물의 농도에 따른 췌장 콜레스테롤 Pancreatic cholesterol levels according to the concentration of water extract 에스터레이즈Esther Reyes 활성 측정 Active measurement
한편, 실시예의 아위버섯의 물 추출물의 농도에 따른 췌장 콜레스테롤 에스터레이즈 활성을 측정하였다. 췌장 콜레스테롤 에스터레이즈에 처리하는 아위버섯 물 추출물의 양을 추출 시 초기 아위버섯 분말 농도를 기준(1%)으로 하여, 1/5배 1/10배, 1/50배로 희석(dilution)했을 때 췌장 콜레스테롤 에스터레이즈 활성 저해 효과를 비교하여, 그 결과를 도 2에 비교하여 나타내었다.
On the other hand, the pancreatic cholesterol ester raising activity was measured according to the concentration of water extract of Astaxanthana mushroom in the examples. When diluted with 1/5, 1 / 10th, and 1/50 of the initial concentration of avidin mushroom powder (1%) when extracting the amount of water-extracted mushroom water from pancreatic cholesterol esterase, The cholesterol esterase inhibitory activity was compared, and the results were shown in comparison with FIG.
<< 실험예3Experimental Example 3 > > 아위버섯Avi mushroom 물 추출물의 농도에 따른 췌장 리파아제 활성 측정 Measurement of pancreatic lipase activity by water extract concentration
췌장 리파아제는 acyl chain을 가지는 기질들을 비 특이적으로 인식하여 acyl chain을 분리하는 역할을 한다. 실시예 아위버섯 물 추출물의 농도에 따른 췌장 리파아제 활성을 측정하기 위하여, 효소로 시그마 케미칼에서 제조된 포오신 판크리틱 리파아제를 사용하였다.Pancreatic lipase plays a role in recognizing acyl chain-bearing substrates nonspecifically and isolating acyl chains. Example To measure the activity of pancreatic lipase according to the concentration of water extract of avipura mushroom, poisin plate crytopic lipase prepared from Sigma chemical was used as an enzyme.
췌장 리파아제가chromo-genic substrate (p-nirophenylbutyrate)을 분해하는 성질을 이용하여 발색 반응을 통해 enzyme의 활성변화를 확인하였다. 효소의 활성 저해 효과는 Microplate reader를 이용하여 405nm의 흡광도의 변화를 통해 측정하고, 추출물 비처리 그룹의 405nm흡광도를 베이스로 하여, 계산하여 %로 나타내었다.Pancreatic lipase degrades the chromo-genic substrate (p-nirophenylbutyrate) and the activity of the enzyme was confirmed by the color reaction. The inhibitory effect of the enzyme was measured using a microplate reader at 405 nm and calculated as% based on the absorbance at 405 nm of the extract-untreated group.
실시예의 아위버섯 물 추출물의 농도에 따른 효소의 활성이 어떻게 달라지는지 측정하였고, 그 결과 실시예의 아위버섯 물 추출물이 농도 의존적으로 췌장 리파아제가 활성을 현저하게 저하시키는 것을 확인하였다. 결과는 도 3에 간단하게 나타내었다.
As a result, it was confirmed that the water extract of A. manganica extract of the Example significantly decreased the activity of pancreatic lipase in a concentration-dependent manner. The results are briefly shown in Fig.
<< 실험예4Experimental Example 4 > 본 발명 > Invention 아위버섯Avi mushroom 물 추출물에 의한 콜레스테롤 흡수 측정 Measurement of cholesterol absorption by water extract
콜레스테롤 에스터레이즈 활성 저해 효과를 보인 실시예의 아위버섯 물 추출물이 개체 수준에서도 효과를 보이는 지 확인하기 위하여 소화관에서의 콜레스테롤 흡수를 측정하였다.Cholesterol absorption in the gastrointestinal tract was measured in order to determine whether the water extract of Astragalus membranaceus in the examples showing inhibition of cholesterol esterase activity was also effective at the individual level.
동위원소(3H)로 표지된 콜레스테롤 올리에이트 (Cholesterol oleate, Amersham, 100 μCi/ml)을 1%(w/v) 카르복실메틸셀룰로오스나트륨(CMC-Na), 1% (v/v) 트윈80 (Tween 80), 비표지된 콜레스테롤 올리에이트와 섞어 개체당 1μCi가 들어가도록 생쥐(mouse)에 경구용 존대를 통해 0.1 mL를 강제투여했다.
Cholesterol oleate labeled with isotope ( 3 H) (Amersham, 100 μCi / ml) was dissolved in 1% (w / v) sodium carboxymethyl cellulose (CMC-Na), 1% 80 (Tween 80), unlabeled cholesterol oleate, and 0.1 mL of the solution was orally administered to mice in an amount of 1 μCi per mouse.
이때 대조군 생쥐(Balb/c 수컷, 8주령, 몸무게 ~25g)에는 콜레스테롤 흡수 저해 효능의 올리스탯(Orlistat) 400 μg (20mg/kg)을, 실험군 생쥐( Balb/c 수컷, 8주령, 몸무게 ~25g)에는 실시예의 아위버섯 물 추출물(10 mg/mL) 20mL을 농축하여 0.1mL을 경구 투여 하였다.At this time, 400 μg of Orlistat (20 mg / kg) of cholesterol absorption inhibitory effect was administered to the control mice (Balb / c male, 8 weeks old and weighing ~ 25 g) ), 20 mL of the water extract of Adi-mushroom (10 mg / mL) of the Example was concentrated and 0.1 mL was orally administered.
6 시간 후 생쥐의 혈액을 채취하여 4℃에서 혈장을 14000rpm 으로 10분 동안 원심 분리하여 얻고, 액체 신틸레이터(Beta counter, Beckman LS1801)를 이용하여 선량을 측정하였다. control 그룹은 콜레스테롤 흡수 저해제로 아무것도 투여하지 않은 그룹이다. control 그룹의 선량을 1로 정하고 각 실험 그룹의 선량을 control그룹의 선량으로 나누었을 때의 상대값으로 지방 흡수량을 정하였다. After 6 hours, the blood of the mice was collected and centrifuged at 14000 rpm for 10 minutes at 4 ° C, and the dose was measured using a liquid scintillator (Beta counter, Beckman LS1801). The control group is a group in which nothing is administered as a cholesterol absorption inhibitor. The dose of the control group was set to 1 and the dose of each experimental group was divided by the dose of the control group.
본 발명에 따른 아위버섯의 물 추출물은 대조군으로 사용한 올리스탯과 마찬가지로 현저한 지방 흡수 저해 효과를 보였다. 결과는 도 4에 비교하여 나타내었다. 참고로, 도 4에서 control은 콜레스테롤 흡수 저해제로 아무것도 투여하지 않은 생쥐의 혈액 채취 결과이다.The water extract of P. falciparum according to the present invention showed remarkable fat absorption inhibitory effect like the olistat used as the control group. The results are shown in comparison with FIG. For reference, in FIG. 4, control is a blood sampling result of a mouse in which nothing is administered as a cholesterol absorption inhibitor.
이하에서 본 발명의 아위버섯의 물 추출물을 유효성분으로 하는 각종 제형의 예를 기재하였으나, 본 발명의 제제가 이에 국한되는 것은 아니다.
Examples of various formulations containing the water extract of Astaxantha mushroom of the present invention as an active ingredient are described below, but the formulations of the present invention are not limited thereto.
제조예Manufacturing example 1. One. 산제의Sanje 제조 Produce
아위버섯 물 추출물 분말 20 mg Artichoke mushroom water extract powder 20 mg
유당 100 mg
탈크 10 mg
상기의 성분들을 혼합하고 기밀포에 충진하여 산제를 제조하였다.
The above ingredients were mixed and filled in an airtight container to prepare powders.
제조예Manufacturing example 2. 2. 정제의 제조Manufacture of tablets
아위버섯 물 추출물 분말 10 mg Ai mushroom
옥수수전분 100 mg
유당 100 mg
스테아린산 마그네슘 2 mg Magnesium stearate 2 mg
상기의 성분들을 혼합한 후 통상의 정제의 제조방법에 따라서 타정하여 정제를 제조하였다.
After mixing the above components, tablets were prepared by tableting according to the usual preparation method of tablets.
제조예Manufacturing example 3. 3. 캡슐제의 제조 Preparation of capsules
아위버섯 물 추출물 분말 10 mg Ai mushroom
결정성 셀룰로오스 3 mg Crystalline cellulose 3 mg
락토오스 14.8 mg Lactose 14.8 mg
마그네슘 스테아레이트 0.2 mg Magnesium stearate 0.2 mg
통상의 캡슐제 제조방법에 따라 상기의 성분을 혼합하고 젤라틴 캡슐에 충전하여 캡슐제를 제조하였다.
The above components were mixed according to a conventional capsule preparation method and filled in gelatin capsules to prepare capsules.
제조예Manufacturing example 4. 4. 액제의Liquid 제조 Produce
아위버섯 물 추출물 분말 20 mg Artichoke mushroom water extract powder 20 mg
이성화당 10 g 10 g per isomer
만니톨 5 g 5 g mannitol
정제수 적량 Purified water quantity
통상의 액제의 제조방법에 따라 정제수에 각각의 성분을 가하여 용해시키고 레몬향을 적량 가한 다음 상기의 성분을 혼합한 다음 정제수를 가하여 전체를 정제수를 가하여 전체 100mL로 조절한 후 갈색병에 충진하여 멸균시켜 액제를 제조하였다. Each component was added to purified water according to the usual liquid preparation method and dissolved, and the lemon flavor was added in an appropriate amount. Then, the above components were mixed, and then purified water was added thereto. The entirety was adjusted to 100 mL by adding purified water, To prepare a liquid agent.
제조예Manufacturing example 5. 5. 주사제의 제조 Injection preparation
아위버섯 물 추출물 분량 10mgWater extract of Ai mushroom 10mg
만니톨 180mg180 mg mannitol
주사용 멸균 증류수 3000mgSterile sterilized water for injection 3000 mg
Na2HPO4, 12H2O 25mgNa 2 HPO 4 , 12H 2 O 25 mg
통상의 주사제의 제조 방법에 따라 1 앰플당(2mL)(2 mL) per ampoule according to the usual injection method,
상기의 성분함량으로 제조한다.
It is prepared with the above ingredient contents.
제조예Manufacturing example 6. 6. 건강 식품의 제조 Manufacture of health food
아위버섯 물 추출물 분말 1000 ㎎ 1000 ㎎ of water extract powder of avi mushroom
비타민 혼합물 적량 Vitamin mixture quantity
비타민 A 아세테이트 70 ㎍ 70 [mu] g of vitamin A acetate
비타민 E 1.0 ㎎ Vitamin E 1.0 mg
비타민 B1 0.13 ㎎ 0.13 mg vitamin B1
비타민 B2 0.15 ㎎ 0.15 mg of vitamin B2
비타민 B6 0.5 ㎎ 0.5 mg vitamin B6
비타민 B12 0.2 ㎍ 0.2 [mu] g vitamin B12
비타민 C 10 ㎎ 10 mg vitamin C
비오틴 10 ㎍ Biotin 10 μg
니코틴산아미드 1.7 ㎎ Nicotinic acid amide 1.7 mg
엽산 50 ㎍ 50 ㎍ of folic acid
판토텐산 칼슘 0.5 ㎎ Calcium pantothenate 0.5 mg
무기질 혼합물 적량 Mineral mixture quantity
황산제1철 1.75 ㎎ 1.75 mg of ferrous sulfate
산화아연 0.82 ㎎ 0.82 mg of zinc oxide
탄산마그네슘 25.3 ㎎ Magnesium carbonate 25.3 mg
제1인산칼륨 15 ㎎ 15 mg of potassium phosphate monobasic
제2인산칼슘 55 ㎎ Secondary calcium phosphate 55 mg
구연산칼륨 90 ㎎ Potassium citrate 90 mg
탄산칼슘 100 ㎎ 100 mg of calcium carbonate
염화마그네슘 24.8 ㎎
24.8 mg of magnesium chloride
상기의 비타민 및 미네랄 혼합물의 조성비는 비교적 건강식품에 적합한 성분을 바람직한 실시예로 혼합 조성하였지만, 그 배합비를 임의로 변형 실시하여도 무방하며, 통상의 건강식품 제조방법에 따라 상기의 성분을 혼합한 다음, 과립을 제조하고, 통상의 방법에 따라 건강식품 조성물 제조에 사용할 수 있다.Although the composition ratio of the above-mentioned vitamin and mineral mixture is comparatively mixed with a composition suitable for health food as a preferred embodiment, the compounding ratio may be arbitrarily modified, and the above ingredients are mixed according to a conventional method for producing healthy foods , Granules can be prepared and used in the manufacture of health food compositions according to conventional methods.
Claims (8)
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/KR2012/010792 WO2013089429A1 (en) | 2011-12-12 | 2012-12-12 | Composition for preventing or treating hyperlipidemia containing water extract of pleurotus eryngii var. ferulae as active ingredient |
CN201280061440.7A CN104023734A (en) | 2011-12-12 | 2012-12-12 | Composition for preventing or treating hyperlipedemia containing a water extract of Pleurotus eryngii var. ferulae as active ingredient |
JP2014545832A JP2015502954A (en) | 2011-12-12 | 2012-12-12 | A composition for preventing or treating dyslipidemia, comprising an aqueous extract of Aguitake as an active ingredient |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020110132728 | 2011-12-12 | ||
KR20110132728 | 2011-12-12 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020150055605A Division KR20150048698A (en) | 2015-04-21 | 2015-04-21 | Composition Comprising Water Extracts from Pleurotus eryngii var. ferulea (Pf.). for Treating or Preventing hyperlipidemia |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20130066535A KR20130066535A (en) | 2013-06-20 |
KR101565964B1 true KR101565964B1 (en) | 2015-11-16 |
Family
ID=48862761
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020120143701A KR101565964B1 (en) | 2011-12-12 | 2012-12-11 | Composition Comprising Water Extracts from Pleurotus eryngii var. ferulea (Pf.). for Treating or Preventing hyperlipidemia |
Country Status (3)
Country | Link |
---|---|
JP (1) | JP2015502954A (en) |
KR (1) | KR101565964B1 (en) |
CN (1) | CN104023734A (en) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101634200B1 (en) * | 2014-05-22 | 2016-07-11 | 포항공과대학교 산학협력단 | COMPOSITION COMPRISING ALCOHOL EXTRACTS FROM Bjerkandera adusta. FOR TREATING OR PREVENTING HYPERLIPIDEMIA |
KR20160141027A (en) * | 2015-05-27 | 2016-12-08 | 경상북도 | Phamaceutical composition or healthy food comprising water extracts from Pleurotus eryngii var. ferulea (Pf.). for treating or preventing metabolic disorder |
KR101706516B1 (en) * | 2016-12-14 | 2017-02-15 | 포항공과대학교 산학협력단 | COMPOSITION COMPRISING WATER EXTRACTS FROM Lactarius Volemus FOR TREATING OR PREVENTING OBESITY |
KR102429280B1 (en) * | 2020-06-29 | 2022-08-05 | (주)노바셀테크놀로지 | Phamaceutical composition and health functional food for preventing or treating obesity comprising powder of a novel hydridized mushroomstrain |
KR102624698B1 (en) * | 2022-05-23 | 2024-01-12 | 하송윤 | A manufacturing method of functional drinking water additive |
CN118452451B (en) * | 2024-07-15 | 2024-09-27 | 浙江衡美健康科技股份有限公司 | Weight-reducing composition for inhibiting fat absorption, food preparation and application |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002087981A (en) | 2000-07-11 | 2002-03-27 | Hitoshi Nagaoka | Improving agent for metabolic disorder against sugar and lipid |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6372462B2 (en) * | 1999-10-15 | 2002-04-16 | Medmyco Ltd. | Process for producing, methods and compositions of cholesterol lowering agents from higher basidiomycetes mushrooms |
CA2414912A1 (en) * | 2001-12-20 | 2003-06-20 | University Of Saskatchewan Technologies Inc. | Pleurotus extract and use in treating hypertension |
CN101164452B (en) * | 2006-10-17 | 2012-03-14 | 天津科技大学 | Double-preparation type composite mushroom functional beverage host and preparation method thereof |
CN102406686A (en) * | 2007-10-24 | 2012-04-11 | 三得利控股株式会社 | Ligand agents for peroxisome proliferator-activated receptors (ppars) |
CN101914168B (en) * | 2010-09-06 | 2013-06-19 | 石河子大学 | Medical applications and preparation methods of Pleurotus ferulae Lanzi polysaccharide and composites thereof |
-
2012
- 2012-12-11 KR KR1020120143701A patent/KR101565964B1/en active IP Right Grant
- 2012-12-12 JP JP2014545832A patent/JP2015502954A/en active Pending
- 2012-12-12 CN CN201280061440.7A patent/CN104023734A/en active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002087981A (en) | 2000-07-11 | 2002-03-27 | Hitoshi Nagaoka | Improving agent for metabolic disorder against sugar and lipid |
Also Published As
Publication number | Publication date |
---|---|
CN104023734A (en) | 2014-09-03 |
KR20130066535A (en) | 2013-06-20 |
JP2015502954A (en) | 2015-01-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101490786B1 (en) | Composition comprising water extracts from fomitella fraxinea (fr.) imaz. for treating or preventing obesity | |
KR101565964B1 (en) | Composition Comprising Water Extracts from Pleurotus eryngii var. ferulea (Pf.). for Treating or Preventing hyperlipidemia | |
KR20160141027A (en) | Phamaceutical composition or healthy food comprising water extracts from Pleurotus eryngii var. ferulea (Pf.). for treating or preventing metabolic disorder | |
KR101490781B1 (en) | Composition comprsing alcohol extracts from albatrellus dispansus for treating or preventing hyperlipidemia | |
KR101490794B1 (en) | Composition comprising alcohol extracts from oligoporus tephroleucus for treating or preventing hyperlipidemia | |
KR20150048698A (en) | Composition Comprising Water Extracts from Pleurotus eryngii var. ferulea (Pf.). for Treating or Preventing hyperlipidemia | |
KR101594649B1 (en) | Composition comprising alcohol extracts from ramaria stricta for treating or preventing hyperlipidemia | |
KR101691256B1 (en) | COMPOSITION COMPRISING ALCOHOL EXTRACTS FROM Oligoporus stipticus, FOR TREATING OR PREVENTING HYPERLIPIDEMIA | |
KR20130065117A (en) | Composition comprising water extracts from tremella foliacea fr. for treating or preventing obesity | |
KR101490800B1 (en) | Composition comprising water extracts from laetiporus sulphureus var. miniatus (jungh.) imaz. for treating or preventing hyperlipidemia | |
KR101706516B1 (en) | COMPOSITION COMPRISING WATER EXTRACTS FROM Lactarius Volemus FOR TREATING OR PREVENTING OBESITY | |
KR101773221B1 (en) | Composition comprising alcohol extracts from russula japonica for treating or preventing hyperlipidemia | |
KR101490792B1 (en) | Composition comprsing alcohol extracts from hapalopilus rutilans for treating or preventing obesity | |
KR101706431B1 (en) | COMPOSITION COMPRISING WATER EXTRACTS FROM Lactarius Volemus FOR TREATING OR PREVENTING HYPERLIPIDEMIA | |
KR101625280B1 (en) | COMPOSITION COMPRSING ALCOHOL EXRACTS FROM Albatrellus fletti FOR TREATING OR PREVENTING OBESITY | |
KR101626191B1 (en) | Composition comprising water extracts from suillus bovinus for treating or preventing hyperlipidemia | |
KR101569254B1 (en) | composition comprising water extracts from oudemansiella platyphylla for treating or preventing hyperlipidemia | |
KR101598668B1 (en) | Composition comprising alcohol extracts from clavicorona pyxidata for treating or preventing hyperlipidemia | |
KR101634200B1 (en) | COMPOSITION COMPRISING ALCOHOL EXTRACTS FROM Bjerkandera adusta. FOR TREATING OR PREVENTING HYPERLIPIDEMIA | |
KR20190015423A (en) | Phamaceutical composition or healthy food comprising water extracts from Pleurotus eryngii var. ferulae (Pf.). for treating or preventing metabolic disorder | |
KR20170116597A (en) | COMPOSITION COMPRISING WATER EXTRACTS FROM pleurotus cornucopiae(paulet) Rolland FOR TREATING OR PREVENTING HYPERLIPIDEMIA | |
KR20170087064A (en) | Phamaceutical composition or healthy food comprising water extracts from Pleurotus eryngii var. ferulea (Pf.). for treating or preventing metabolic disorder | |
KR20160104590A (en) | Composition comprising alcohol extracts from russula japonica for treating or preventing hyperlipidemia | |
KR20170039635A (en) | COMPOSITION COMPRISING WATER EXTRACTS FROM pleurotus cornucopiae FOR TREATING OR PREVENTING HYPERLIPIDEMIA | |
KR20160075902A (en) | COMPOSITION COMPRISING ALCOHOL EXTRACTS FROM Fomitopsis sp. FOR TREATING OR PREVENTING HYPERLIPIDEMIA |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
AMND | Amendment | ||
E601 | Decision to refuse application | ||
AMND | Amendment | ||
E801 | Decision on dismissal of amendment | ||
E90F | Notification of reason for final refusal | ||
AMND | Amendment | ||
X701 | Decision to grant (after re-examination) | ||
FPAY | Annual fee payment |
Payment date: 20181001 Year of fee payment: 4 |
|
FPAY | Annual fee payment |
Payment date: 20190925 Year of fee payment: 5 |